Inter-species differences in drug properties

Chemico-Biological Interactions

Volumn 134, Issue 3, 2001, Pages 237-242

  Collins, Jerry M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DOXORUBICIN DERIVATIVE; IODODEOXYDOXORUBICIN; PACLITAXEL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; NONHUMAN; RELIABILITY; RISK ASSESSMENT; SPECIES DIFFERENCE;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYLAMINE N-ACETYLTRANSFERASE; DOGS; DOXORUBICIN; HUMANS; PACLITAXEL; PHARMACEUTICAL PREPARATIONS; RESEARCH; SPECIES SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; ZIDOVUDINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0035897707     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(01)00158-2     Document Type: Article

References (7)

1. Overview: Hepatocytes and cryopreservation - A personal historical perspective
2. Understanding consequences of concurrent therapies
3. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases
4. Pharmacokinetics and bioavailability of zidovudine in humans
5. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences
6. Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in Phase I trials
7. Targeted inhibition of N-acetyltransferases (NAT1, NAT2) in human hepatocytes and cytosol